226 related articles for article (PubMed ID: 24430948)
21. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-RubiĆ³ P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
22. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
23. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Li YP; Zhang LR; Jia M; Hu XJ
J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697
[TBL] [Abstract][Full Text] [Related]
24. Hemostatic effects of atorvastatin versus simvastatin.
Kadikoylu G; Yukselen V; Yavasoglu I; Bolaman Z
Ann Pharmacother; 2003 Apr; 37(4):478-84. PubMed ID: 12659599
[TBL] [Abstract][Full Text] [Related]
25. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
26. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
28. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
29. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
Mirdamadi HZ; Sztanek F; Derdak Z; Seres I; Harangi M; Paragh G
Br J Clin Pharmacol; 2008 Sep; 66(3):366-74. PubMed ID: 18492126
[TBL] [Abstract][Full Text] [Related]
30. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
[TBL] [Abstract][Full Text] [Related]
31. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
Farnier M; Portal JJ; Maigret P
J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):27-32. PubMed ID: 10687671
[TBL] [Abstract][Full Text] [Related]
33. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
34. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
Wierzbicki AS; Mikhailidis DP
Int J Cardiol; 2002 Jul; 84(1):53-7. PubMed ID: 12104065
[TBL] [Abstract][Full Text] [Related]
35. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.
Gao Y; Zhang LR; Fu Q
Eur J Clin Pharmacol; 2008 Sep; 64(9):877-82. PubMed ID: 18528690
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide association of lipid-lowering response to statins in combined study populations.
Barber MJ; Mangravite LM; Hyde CL; Chasman DI; Smith JD; McCarty CA; Li X; Wilke RA; Rieder MJ; Williams PT; Ridker PM; Chatterjee A; Rotter JI; Nickerson DA; Stephens M; Krauss RM
PLoS One; 2010 Mar; 5(3):e9763. PubMed ID: 20339536
[TBL] [Abstract][Full Text] [Related]
37. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Rader DJ; Davidson MH; Caplan RJ; Pears JS
Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
[TBL] [Abstract][Full Text] [Related]
38. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Hilleman DE; Wurdeman RL; Lenz TL
Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
[TBL] [Abstract][Full Text] [Related]
40. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]